Darovasertib + Crizotinib in First-Line Metastatic Uveal Melanoma

Market
0.0%
100%75%50%25%0%Apr 12 • YES 59.2%Apr 12
Trade

Will the results be positive?

Paper Trading
DetailsModel PositionsModel SnapshotsOracle
Details
Primary Completion
1/15/27
Study Completion
1/15/28
Company
IDEAYA Biosciences
Ticker
IDYA
Type
Phase 2/Phase 3
Trial Status
Active Not Recruiting
Trial Size
420
Volume
$173K
NCT
NCT05987332
Drug Description
This is a randomized, open-label Phase 2/3 study in HLA-A*02:01-negative metastatic uveal melanoma comparing darovasertib plus crizotinib against investigator's choice of pembrolizumab, ipilimumab plus nivolumab, or dacarbazine. The study includes an initial dose-optimization stage, a Phase 2 PFS assessment, and a Phase 3 OS assessment.